
Kelun-Biotech's Trastuzumab Botidotin Outperforms T-DM1 in Phase III Trial
A landmark Phase III study published in the Journal of Clinical Oncology confirms that the domestically developed antibody–drug conjugate trastuzumab botidotin significantly extends progression-free survival in patients with HER2-positive metastatic breast cancer when compared to the current standard of care, trastuzumab emtansine (T-DM1).















